Loading...
Docoh

Karuna Therapeutics (KRTX)

News

From Benzinga Pro
Karuna Therapeutics: Q1 Earnings Insights
5 May 22
Earnings, News
Karuna Therapeutics (NASDAQ:KRTX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Karuna Therapeutics Q1 EPS $(1.95) Down From $(1.10) YoY
5 May 22
Earnings, News
Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(1.95) per share. This is a 77.27 percent decrease over losses of $(1.10) per share from the same period last year.
What 4 Analyst Ratings Have To Say About Karuna Therapeutics
27 Apr 22
Analyst Ratings
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:
Mizuho Maintains Buy on Karuna Therapeutics, Raises Price Target to $190
27 Apr 22
News, Price Target, Analyst Ratings
Mizuho analyst Vamil Divan maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $178 to $190.
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
31 Mar 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Berenberg Initiates Coverage On Karuna Therapeutics with Buy Rating, Announces Price Target of $190
31 Mar 22
News, Price Target, Initiation, Analyst Ratings
Berenberg initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and announces Price Target of $190.
Jefferies Maintains Buy on Karuna Therapeutics, Raises Price Target to $183
8 Mar 22
News, Price Target, Analyst Ratings
Jefferies analyst Chris Howerton maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $180 to $183.
Mizuho Maintains Buy on Karuna Therapeutics, Lowers Price Target to $178
3 Mar 22
News, Price Target, Analyst Ratings
Mizuho analyst Vamil Divan maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and lowers the price target from $182 to $178.
Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
24 Feb 22
Biotech, Earnings, News, Health Care, Movers, Trading Ideas, General
Karuna Therapeutics Q4 EPS $(0.94) Down From $(0.89) YoY
24 Feb 22
Earnings, News
Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(0.94) per share. This is a 5.62 percent decrease over losses of $(0.89) per share from the same period last year.

Press releases

From Benzinga Pro
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease
18 May 22
Press Releases
Webcast scheduled for Wednesday, May 25, 2022, at 8:00 a.m. ET Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living
Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
5 May 22
Press Releases
Completed enrollment in the Phase 3 EMERGENT-2 trial evaluating KarXT for the treatment of schizophrenia in the second quarter of 2022 Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in the
Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference
3 May 22
Press Releases
Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
Karuna Therapeutics to Present at Upcoming Investor Conferences
10 Mar 22
Press Releases
Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced
Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update
24 Feb 22
Press Releases
Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively Initiated the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who